4//SEC Filing
Huizinga Robert Bindert 4
Accession 0001628280-21-020527
CIK 0001600620other
Filed
Oct 25, 8:00 PM ET
Accepted
Oct 26, 4:33 PM ET
Size
8.9 KB
Accession
0001628280-21-020527
Insider Transaction Report
Form 4
Huizinga Robert Bindert
EVP of Research
Transactions
- Sale
Common Stock
2021-10-25$29.75/sh−130,000$3,867,500→ 65,728 total - Exercise/Conversion
Stock Option (right to buy)
2021-10-25−95,000→ 3,864 totalExercise: $3.20Exp: 2027-02-09→ Common Stock (95,000 underlying) - Exercise/Conversion
Common Stock
2021-10-25$3.20/sh+95,000$304,000→ 195,728 total
Footnotes (4)
- [F1]Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F3]The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $29.50 to $30.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]The shares subject to the option are fully vested and immediately exercisable. They vested in thirty-six equal monthly installments from the grant date.
Documents
Issuer
Aurinia Pharmaceuticals Inc.
CIK 0001600620
Entity typeother
Related Parties
1- filerCIK 0001837648
Filing Metadata
- Form type
- 4
- Filed
- Oct 25, 8:00 PM ET
- Accepted
- Oct 26, 4:33 PM ET
- Size
- 8.9 KB